Kingdon Capital Management L.L.C. Has $18.37 Million Stock Holdings in Humana Inc. $HUM

Kingdon Capital Management L.L.C. lifted its stake in shares of Humana Inc. (NYSE:HUM) by 9.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 70,600 shares of the insurance provider’s stock after purchasing an additional 6,000 shares during the period. Humana accounts for 2.3% of Kingdon Capital Management L.L.C.’s holdings, making the stock its 8th biggest position. Kingdon Capital Management L.L.C.’s holdings in Humana were worth $18,368,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Illinois Municipal Retirement Fund increased its position in shares of Humana by 9.6% in the third quarter. Illinois Municipal Retirement Fund now owns 49,658 shares of the insurance provider’s stock worth $12,920,000 after purchasing an additional 4,351 shares during the period. Bank of New York Mellon Corp increased its position in Humana by 161.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,717,767 shares of the insurance provider’s stock valued at $446,911,000 after acquiring an additional 1,060,767 shares during the period. National Pension Service lifted its holdings in Humana by 2.8% in the third quarter. National Pension Service now owns 189,601 shares of the insurance provider’s stock valued at $49,328,000 after buying an additional 5,150 shares during the period. Tejara Capital Ltd bought a new stake in Humana in the third quarter worth approximately $1,873,000. Finally, AMG National Trust Bank lifted its position in shares of Humana by 106.5% during the 3rd quarter. AMG National Trust Bank now owns 16,953 shares of the insurance provider’s stock valued at $4,411,000 after acquiring an additional 8,744 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

HUM opened at $165.38 on Monday. The stock has a market capitalization of $19.85 billion, a P/E ratio of 16.84, a P/E/G ratio of 1.77 and a beta of 0.44. The company’s 50-day simple moving average is $212.90 and its two-hundred day simple moving average is $247.52. Humana Inc. has a 52-week low of $163.60 and a 52-week high of $315.35. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The business’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same period last year, the firm posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Friday, March 27th. Humana’s payout ratio is currently 36.05%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Oppenheimer set a $250.00 price objective on Humana in a research note on Thursday, February 12th. UBS Group reiterated a “neutral” rating on shares of Humana in a research report on Wednesday, February 25th. Sanford C. Bernstein restated an “outperform” rating and set a $344.00 price target on shares of Humana in a research report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft set a $180.00 price objective on Humana and gave the company a “hold” rating in a research note on Friday, February 13th. Finally, Guggenheim cut their target price on Humana from $312.00 to $252.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Humana has an average rating of “Hold” and a consensus target price of $225.48.

Insider Buying and Selling at Humana

In other news, insider Sanjay K. Shetty acquired 810 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were purchased at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the transaction, the insider directly owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.20% of the stock is currently owned by insiders.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.